Scinai Immunotherapeutics Ltd.(SCNI)Earnings, Financials & Key Ratios
SCNI•NASDAQ
$0.54
$714770 mkt cap·Price updated May 7, 2026
AboutScinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Show more
- Revenue$1M+99.2%
- EBITDA-$6M+12.4%
- Net Income-$8M-273.2%
- EPS (Diluted)-3.60-160.0%
- Gross Margin-202.29%-129.5%
- EBITDA Margin-466.9%+56.0%
- Operating Margin-575.29%+56.2%
- Net Margin-633.64%-186.9%
- ROE-91.89%-151.8%
- ROIC-60.15%+1.5%
- Debt/Equity0.28+33.8%
- Interest Coverage-22.14-268.8%
SCNI Key Insights
Scinai Immunotherapeutics Ltd. (SCNI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 42.7%
- ✓Healthy 5Y average net margin of 47.6%
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 43.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 12 (bottom 12%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SCNI Price & Volume
Scinai Immunotherapeutics Ltd. (SCNI) stock price & volume — 10-year historical chart
Loading chart...
SCNI Growth Metrics
Scinai Immunotherapeutics Ltd. (SCNI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM303.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM210.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Return on Capital
10 Years-54.9%
5 Years-60.22%
3 Years-60.26%
Last Year-69.57%
SCNI Peer Comparison
Scinai Immunotherapeutics Ltd. (SCNI) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.5B | 9.23 | 3.63 | 64.69% | -14.73% | |||
 DYAI | 26.96M | 0.75 | -3.73 | 20.58% | -279.56% | -281.83% | 2.05 | |
 IBIO | 25.89M | 1.64 | -0.94 | 77.78% | -82.46% | -71.26% | 0.24 | |
 VXRT | 177.97M | 0.74 | 10.57 | 7.27% | 6.88% | 33.83% | 0.10 | |
 MNOV | 70.14M | 1.43 | -5.96 | -29.29% | -28.85% | 0.00 | ||
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% |
Compare SCNI vs Peers
Scinai Immunotherapeutics Ltd. (SCNI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SCNI Income Statement
Scinai Immunotherapeutics Ltd. (SCNI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 658K | 1.31M | 1.15M |
| Revenue Growth % | - | - | - | - | - | - | - | - | 99.24% | 303.87% |
| Cost of Goods Sold | 123.55K | 72.32K | 461.69K | 708.92K | 747.65K | 559.8K | 512.67K | 1.24M | 3.96M | 2.83M |
| COGS % of Revenue | - | - | - | - | - | - | - | 188.15% | 302.29% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -708.92K▲ 0% | -747.65K▼ 5.5% | -559.8K▲ 25.1% | -512.67K▲ 8.4% | -580K▼ 13.1% | -2.65M▼ 357.2% | -1.69M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | -88.15% | -202.29% | -146.99% |
| Gross Profit Growth % | - | - | - | - | -5.46% | 25.13% | 8.42% | -13.13% | -357.24% | - |
| Operating Expenses | 6.8M | 20.61M | 22.69M | -2.28M | 10.86M | 11.06M | 9.71M | 8.06M | 4.89M | 6.76M |
| OpEx % of Revenue | - | - | - | - | - | - | - | 1224.62% | 373% | - |
| Selling, General & Admin | 1.4M | 1.38M | 2.81M | 5.02M | 7.63M | 5.3M | 4.5M | 2.53M | 2.52M | 2.65M |
| SG&A % of Revenue | - | - | - | - | - | - | - | 383.89% | 192.3% | - |
| Research & Development | 5.58M | 19.27M | 19.88M | 16.01M | 3.25M | 5.76M | 5.21M | 5.53M | 2.37M | 4.65M |
| R&D % of Revenue | - | - | - | - | - | - | - | 840.73% | 180.7% | - |
| Other Operating Expenses | -186K | -38.24K | 0 | -23.31M | -12K | 0 | -9K | 0 | 0 | -539.9K |
| Operating Income | -6.8M▲ 0% | -20.61M▼ 203.1% | -22.69M▼ 10.1% | 2.28M▲ 110.1% | -10.87M▼ 576.5% | -11.06M▼ 1.7% | -9.71M▲ 12.3% | -8.64M▲ 11.0% | -7.54M▲ 12.7% | -8.45M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | -1312.77% | -575.29% | -736.36% |
| Operating Income Growth % | -120.07% | -203.15% | -10.1% | 110.06% | -576.51% | -1.72% | 12.25% | 11% | 12.69% | - |
| EBITDA | -6.67M | -20.54M | -22.23M | 2.75M | -10.4M | -10.5M | -9.19M | -6.99M | -6.12M | -6.75M |
| EBITDA Margin % | - | - | - | - | - | - | - | -1062.16% | -466.9% | -588.06% |
| EBITDA Growth % | -128.05% | -207.68% | -8.24% | 112.37% | -478.21% | -0.92% | 12.45% | 23.97% | 12.42% | -491.15% |
| D&A (Non-Cash Add-back) | 123.55K | 72.32K | 461.69K | 468.56K | 471K | 562K | 514K | 1.65M | 1.42M | 1.7M |
| EBIT | -6.8M | -20.61M | -22.69M | 2.28M | -10.86M | -11.06M | -9.71M | -8.64M | -7.95M | 7.1M |
| Net Interest Income | 5.17K | -2.43M | -4.27M | -348K | -3.36M | 3.05M | 115K | -1.34M | -339K | 12.65M |
| Interest Income | 5.04K | 1.35M | 8.3K | 582 | 929 | 8.1M | 122.68K | 100.47K | 20K | 14.77M |
| Interest Expense | 20.45K | 3.78M | 4.28M | 348.93K | 3.36M | 5.05M | 7.98K | 1.44M | 359K | 2.12M |
| Other Income/Expense | -3.13M | -2.85M | -8.93M | -3.67M | 2.67M | 5.26M | 3.21M | 13.43M | -765K | 12.54M |
| Pretax Income | -9.93M▲ 0% | -23.46M▼ 136.2% | -31.62M▼ 34.8% | -1.39M▲ 95.6% | -8.21M▼ 492.1% | -5.8M▲ 29.4% | -6.5M▼ 12.1% | 4.8M▲ 173.8% | -8.31M▼ 273.2% | 4.09M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | 728.88% | -633.64% | 356.67% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -9.93M▲ 0% | -23.46M▼ 136.2% | -31.62M▼ 34.8% | -1.39M▲ 95.6% | -8.21M▼ 492.1% | -5.8M▲ 29.4% | -6.5M▼ 12.1% | 4.8M▲ 173.8% | -8.31M▼ 273.2% | 4.09M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | 728.88% | -633.64% | 356.67% |
| Net Income Growth % | -316.53% | -136.24% | -34.79% | 95.62% | -492.06% | 29.37% | -12.15% | 173.78% | -273.21% | 210.45% |
| Net Income (Continuing) | -9.93M | -23.46M | -31.62M | -1.39M | -8.21M | -5.8M | -6.5M | 4.8M | -8.31M | 4.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -790280.00▲ 0% | -999999.00▼ 26.5% | -999999.00▲ 0.0% | -12.40▲ 100.0% | -80.00▼ 545.2% | -30.80▲ 61.5% | -16.80▲ 45.5% | 6.00▲ 135.7% | -3.60▼ 160.0% | 2.57▲ 0% |
| EPS Growth % | -179.92% | -81.68% | -7.87% | 100% | -545.16% | 61.5% | 45.45% | 135.71% | -160% | -100% |
| EPS (Basic) | -790280.00 | -999999.00 | -999999.00 | -12.40 | -80.00 | -30.80 | -16.80 | 6.00 | -3.60 | - |
| Diluted Shares Outstanding | 50.26K | 65.36K | 81.66K | 110.81K | 141.14K | 188.52K | 390.66K | 806.37K | 2.33M | 1.59M |
| Basic Shares Outstanding | 50.26K | 65.35K | 81.66K | 110.81K | 102.57K | 188.52K | 390.66K | 806.37K | 2.33M | 1.59M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SCNI Balance Sheet
Scinai Immunotherapeutics Ltd. (SCNI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 21.64M | 20.55M | 21.17M | 3.31M | 17.84M | 14.37M | 5.45M | 2.39M | 2.05M | 1.51M |
| Cash & Short-Term Investments | 20.51M | 20.29M | 20.98M | 2.93M | 17.37M | 14.07M | 4.87M | 1.96M | 1.66M | 989K |
| Cash Only | 20.51M | 20.29M | 20.98M | 2.93M | 17.37M | 14.07M | 4.87M | 1.96M | 1.66M | 989K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 71.22K | 325.15K | 0 | 330K | 217K | 168K | 139K |
| Days Sales Outstanding | - | - | - | - | - | - | - | 120.37 | 46.77 | 48.93 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 911.89K | 102.42K | 101.06K | 33 | -84.15K | 250K | 176K | 131K | 150K | 142K |
| Total Non-Current Assets | 1.84M | 7.75M | 12.34M | 14.4M | 14.19M | 12.7M | 12.03M | 11.06M | 9.57M | 10.33M |
| Property, Plant & Equipment | 1.58M | 7.55M | 12.19M | 14.25M | 14.19M | 12.7M | 12.03M | 11.06M | 9.57M | 10.33M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.06x | 0.14x | 0.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 147.31K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 252.9K | 197.88K | 150.16K | -150 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 23.48M▲ 0% | 28.3M▲ 20.5% | 33.52M▲ 18.4% | 17.71M▼ 47.2% | 32.04M▲ 80.9% | 27.07M▼ 15.5% | 17.47M▼ 35.4% | 13.45M▼ 23.0% | 11.63M▼ 13.5% | 11.84M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.05x | 0.11x | 0.09x |
| Asset Growth % | 200.42% | 20.54% | 18.43% | -47.17% | 80.93% | -15.51% | -35.45% | -23.03% | -13.55% | -107.88% |
| Total Current Liabilities | 1.98M | 5.83M | 5.49M | 19.97M | 2.44M | 2.34M | 1.78M | 1.81M | 1.58M | 2.12M |
| Accounts Payable | 1.79M | 5.54M | 4.94M | 581.19K | 999K | 716K | 535K | 376K | 407K | 659K |
| Days Payables Outstanding | 5.28K | 27.97K | 3.91K | 299.24 | 487.71 | 466.84 | 380.89 | 110.86 | 37.49 | 68.41 |
| Short-Term Debt | 0 | 0 | 0 | 18.8M | 248.36K | 0 | 396K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 225K | 90K | 225K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | -248.36K | 0 | -396K | 0 | 0 | 964K |
| Current Ratio | 10.94x | 3.53x | 3.86x | 0.17x | 7.30x | 6.15x | 3.06x | 1.32x | 1.30x | 1.30x |
| Quick Ratio | 10.94x | 3.53x | 3.86x | 0.17x | 7.30x | 6.15x | 3.06x | 1.32x | 1.30x | 1.30x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -19.49 |
| Total Non-Current Liabilities | 5.33M | 30.82M | 46.87M | 2.28M | 28.61M | 26.49M | 20.26M | 1.67M | 1.94M | 1.86M |
| Long-Term Debt | 0 | 25.23M | 35.84M | 0 | 27.16M | 20.08M | 19.37M | 260K | 294K | 293K |
| Capital Lease Obligations | 0 | 0 | 1.97M | 1.89M | 1.45M | 1.08M | 797K | 1.4M | 1.64M | 5.12M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.33M | 5.59M | 9.06M | 382.69K | 30.52K | 5.33M | 96K | 3K | 0 | 12K |
| Total Liabilities | 7.31M | 36.65M | 52.36M | 22.25M | 31.05M | 28.83M | 22.04M | 3.47M | 3.52M | 3.98M |
| Total Debt | 0 | 25.23M | 38.02M | 20.9M | 29.23M | 21.54M | 20.56M | 2.09M | 2.27M | 2.36M |
| Net Debt | -20.51M | 4.94M | 17.03M | 17.97M | 11.86M | 7.47M | 15.69M | 122K | 606K | 1.37M |
| Debt / Equity | - | - | - | - | 29.77x | - | - | 0.21x | 0.28x | 0.28x |
| Debt / EBITDA | - | - | - | 7.60x | - | - | - | - | - | -0.35x |
| Net Debt / EBITDA | - | - | - | 6.53x | - | - | - | - | - | -0.20x |
| Interest Coverage | -332.39x | -5.45x | -5.30x | 6.54x | -3.23x | -2.19x | -1216.44x | -6.00x | -22.14x | 3.35x |
| Total Equity | 16.17M▲ 0% | -8.35M▼ 151.6% | -18.84M▼ 125.7% | -4.54M▲ 75.9% | 982K▲ 121.6% | -1.76M▼ 279.2% | -4.57M▼ 159.6% | 9.98M▲ 318.4% | 8.1M▼ 18.8% | 7.86M▲ 0% |
| Equity Growth % | 143.15% | -151.63% | -125.68% | 75.89% | 121.62% | -279.23% | -159.6% | 318.36% | -18.78% | 1251.42% |
| Book Value per Share | 321.66 | -127.72 | -230.68 | -40.98 | 6.96 | -9.34 | -11.70 | 12.37 | 3.47 | 4.94 |
| Total Shareholders' Equity | 16.17M | -8.35M | -18.84M | -4.54M | 982K | -1.76M | -4.57M | 9.98M | 8.1M | 7.86M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -35.47M | -56.46M | -92.76M | -101.05M | -110.04M | -115.83M | -122.33M | -117.54M | -125.85M | -121.67M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | -2.06M | -2.01M | -1.74M | -1.74M | -1.74M | -1.74M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SCNI Cash Flow Statement
Scinai Immunotherapeutics Ltd. (SCNI) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.89M | -15.29M | -22.31M | -22.57M | -7.43M | -7.26M | -9.38M | -6.33M | -6.03M | -6.03M |
| Operating CF Margin % | - | - | - | - | - | - | - | -962.77% | -460.03% | - |
| Operating CF Growth % | -15.28% | -429.52% | -45.9% | -1.14% | 67.1% | 2.17% | -29.14% | 32.48% | 4.8% | 59.2% |
| Net Income | -9.93M | -23.46M | -31.62M | -1.3M | -8.21M | -5.8M | -6.5M | 4.8M | -8.31M | 4.09M |
| Depreciation & Amortization | 126.45K | 69.53K | 476.36K | 757.91K | 471K | 562K | 514K | 1.65M | 1.42M | 1.7M |
| Stock-Based Compensation | 149.16K | 69.53K | 1.07M | 2.95M | 2.76M | 1.6M | 1.14M | 682K | 303K | 619K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7.67M | 7.12M | 7.64M | -25.17M | -3.15M | -4.08M | -3.89M | -13.57M | 389K | -12.82M |
| Working Capital Changes | -901.54K | 902.23K | 126.26K | 196.01K | 701K | 446K | -646K | 112K | 163K | 691K |
| Change in Receivables | -893.21K | 790.99K | 89.48K | -170.5K | 59K | 140K | -290K | 141K | 53K | 71K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -156K | 31K | -54K |
| Cash from Investing | 1.94M | -6.27M | -2.08M | -1.85M | -139K | -836K | -637K | -12K | -24K | -16.02K |
| Capital Expenditures | -1.3M | -6.35M | -2.15M | -1.91M | -139K | -836K | -637K | -12K | -24K | -16.02K |
| CapEx % of Revenue | - | - | - | - | - | - | - | 1.82% | 1.83% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 3.35M | 74.07K | 66.6K | 61.29K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 17.77M | 22.55M | 24.68M | 4.27M | 21.43M | 6.78M | 1.09M | 3.44M | 5.77M | 3.59M |
| Debt Issued (Net) | 0 | 22.55M | 4.27M | -385.8K | -392.62K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 4.35M | 21.43M | 6.75M | 139K | 2M | 5.77M | 2.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 17.77M | 0 | 20.4M | 304.35K | 392.62K | 26.51K | 947K | 1.44M | 0 | 1.57M |
| Net Change in Cash | 16.44M▲ 0% | -222.68K▼ 101.4% | 693.11K▲ 411.3% | -18.05M▼ 2704.7% | 14.44M▲ 180.0% | -3.3M▼ 122.9% | -9.21M▼ 178.8% | -2.92M▲ 68.3% | -284K▲ 90.3% | -3.21M▲ 0% |
| Free Cash Flow | -4.18M▲ 0% | -21.64M▼ 417.2% | -24.47M▼ 13.1% | -24.48M▼ 0.0% | -7.57M▲ 69.1% | -8.1M▼ 7.1% | -10.02M▼ 23.7% | -6.35M▲ 36.7% | -6.05M▲ 4.6% | -5.71M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | -964.59% | -461.86% | -497.38% |
| FCF Growth % | -66.64% | -417.23% | -13.06% | -0.05% | 69.09% | -7.09% | -23.68% | 36.65% | 4.6% | 17.68% |
| FCF per Share | -83.25 | -331.11 | -299.59 | -220.88 | -53.60 | -42.97 | -25.65 | -7.87 | -2.59 | -2.59 |
| FCF Conversion (FCF/Net Income) | 0.29x | 0.65x | 0.71x | 16.28x | 0.90x | 1.25x | 1.44x | -1.32x | 0.73x | -1.39x |
| Interest Paid | 20.98K | 12.3K | 37.93K | 14K | 0 | 916K | 833K | 143K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SCNI Key Ratios
Scinai Immunotherapeutics Ltd. (SCNI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -87.05% | -600.05% | - | - | -835.64% | - | - | 177.37% | -91.89% | 45.84% |
| Return on Invested Capital (ROIC) | - | - | - | 29.46% | -62.1% | -89.45% | -86.51% | -61.06% | -60.15% | -60.15% |
| Gross Margin | - | - | - | - | - | - | - | -88.15% | -202.29% | -146.99% |
| Net Margin | - | - | - | - | - | - | - | 728.88% | -633.64% | 356.67% |
| Debt / Equity | - | - | - | - | 29.77x | - | - | 0.21x | 0.28x | 0.28x |
| Interest Coverage | -332.39x | -5.45x | -5.30x | 6.54x | -3.23x | -2.19x | -1216.44x | -6.00x | -22.14x | 3.35x |
| FCF Conversion | 0.29x | 0.65x | 0.71x | 16.28x | 0.90x | 1.25x | 1.44x | -1.32x | 0.73x | -1.39x |
| Revenue Growth | - | - | - | - | - | - | - | - | 99.24% | 303.87% |
SCNI Frequently Asked Questions
Scinai Immunotherapeutics Ltd. (SCNI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.1M in revenue for fiscal year 2025.
Scinai Immunotherapeutics Ltd. (SCNI) grew revenue by 99.2% over the past year. This is strong growth.
Yes, Scinai Immunotherapeutics Ltd. (SCNI) is profitable, generating $4.1M in net income for fiscal year 2025 (-633.6% net margin).
Dividend & Returns
Scinai Immunotherapeutics Ltd. (SCNI) has a return on equity (ROE) of -91.9%. Negative ROE indicates the company is unprofitable.
Scinai Immunotherapeutics Ltd. (SCNI) had negative free cash flow of $5.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More SCNI
Scinai Immunotherapeutics Ltd. (SCNI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates